Among these health-beneficial roles, its role in protecting and stimulating nerve cells, however, is the most sought after characteristic out of all the other edible mushrooms with medicinal value. Extracts of H.
erinaceus, such as hericenones C-H [18] and [19] and erinacines A-I [20], [21], [22] and [23], have all shown to induce the expression of NGF in cultured rodent astrocytes. Erinacine A, the main representative of the compounds in H. erinaceus extracts, has demonstrated epinephrine-stronger NGF-inducing activities in vitro and in vivo [24]. Furthermore, such NGF stimulating effects have been augmented by the increased availability of the active compound (up to 8 mg/kg body weight) [24], and it has also been achieved via
http://www.selleckchem.com/products/AZD2281(Olaparib).html oral administration [25]. Hence, there is potential in developing H. erinaceus enriched with erinacine A (EAHE) as an ingredient in medicinal foods or products to help in the reduction or even the prevention of age-related neurodegenerative diseases. To our knowledge, there Alpelisib molecular weight have been no reports on the mutagenicity of H. erinaceus prior to this paper. Furthermore, mushroom mycelium has an identity distinct from mushrooms, which are categorized into two specific classes of compounds: hericenones and erinacines, where they can only be extracted from the fruit body and the cultured mycelium, respectively. Our previous
28-day sub-chronic toxicity test in Sprague-Dawley rats showed no evidence of systemic toxicity attributable to EAHE administration [26]. It was estimated that NOAEL (no adverse effect level) of EAHE mycelium is greater than 3 g/kg of body weight/day, which is 171.4 times the recommended daily intake for humans (1.05 g/60 kg of body weight/day). Additional research on EAHE, including an assessment of its Enzalutamide manufacturer mutagenic and carcinogenic potential, however, should be included to further support the safety of its consumption. Evaluation of the genotoxic properties is important in the context of EU and international legislations aiming to protect human health. For an adequate assessment of the genotoxic potential, three endpoints need to be considered: gene mutations, structural chromosome aberrations, and numerical chromosome aberrations. Hence, the present study was undertaken to determine the mutagenicity and genotoxicity effects of EAHE mycelium conducted in three standard battery of tests (reverse mutation, chromosomal aberration, and micronuclei tests) according to the latest guidelines in order to meet all international regulatory requirements and provide information on the safety of this new and promising natural remedy. H.